Short Report

Assessment of Insulin Sensitivity in Adults with Permanent Neonatal Diabetes Mellitus due to Mutations in the KCNJ11 Gene Encoding Kir6.2

Jan Skupien¹, Maciej T. Malecki¹, Wojciech Mlynarski², Tomasz Klupa¹, Krzysztof Wanic¹, Agnieszka Gach², Iwona Solecka¹, Jacek Sieradzki¹

Keywords: neonatal diabetes, mutation, Kir6.2 gene, insulin sensitivity

Abstract

Activating mutations in the KCNJ11 gene encoding the Kir6.2 subunit of ATP-sensitive potassium channel have been described in patients with permanent neonatal diabetes mellitus (PNDM). The main pathophysiological feature of PNDM associated with Kir6.2 mutations is a profound defect in insulin secretion. However, the expression of Kir6.2 protein is not limited to β-cells; it also includes skeletal muscles, heart, brain, and peripheral nerves. Thus, the hypothesis that Kir6.2 mutations may influence insulin sensitivity in humans seems justified. Moreover, this notion is additionally supported by an animal model of Kir6.2 knock-out mice. Four adult carriers of a Kir6.2 mutation from the Polish population (mean age 31.5 years, range 20-50) were available for this study that aimed to evaluate their insulin sensitivity by the hyperinsulinemic euglycemic clamp technique. Three subjects carried the R201H mutation and one patient was a carrier of the K170N mutation. In addition, eight healthy volunteers with normal glucose tolerance were examined for comparison (mean age 31.0 years, range 20-41). The mean M value, i.e. the amount of metabolized glucose, for PNDM cases equaled 4.49 mg/(kg x min) (range 2.76-6.66) and was significantly lower than in the control group (9.64 mg/(kg x min), range 4.59-18.00). This observation suggests that impaired insulin sensitivity, in addition to profoundly decreased insulin secretion, contributes to the clinical picture of PNDM resulting from mutations in the Kir6.2 gene. An additional factor that might influence insulin sensitivity in our diabetes patients is glucose toxicity that may have appeared due to poor metabolic control prior to the examination (mean HbA1c = 8.95%). The intriguing question to be answered in the future is whether an improvement in insulin action could be seen following the transfer of Kir6.2 mutation carriers to sulphonylurea compounds.

Fulltext: HTML , PDF (198KB)

This article has been cited by other articles:

	Down-regulation of Kir6.2 affects calcium influx and insulin secretion in HIT-T15 cells Chen F, Zheng D, Xu Y, Luo Y, Li H, Yu K, Song Y, Zhong W, Ji Y J Pediatr Endocrinol Metab 2010. 23(7):709-717
	The molecular mechanisms and pharmacotherapy of ATP-sensitive potassium channel gene mutations underlying neonatal diabetes Lang V, Light PE Pharmgenomics Pers Med 2010. 3:145-161
	Mutations in the ABCC8 gene are associated with a variable clinical phenotype Klupa T, Kowalska I, Wyka K, Skupien J, Patch AM, Flanagan SE, Noczynska A, Arciszewska M, Ellard S, Hattersley AT, Sieradzki J, Mlynarski W, Malecki MT Clin Endocrinol (Oxf) 2008. Nov 13, epub ahead of print
	Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism Flanagan SE, Clauin S, Bellanne-Chantelot C, de Lonlay P, Harries LW, Gloyn AL, Ellard S Hum Mutat 2008. 30(2):170-180
	Neonatal diabetes mellitus Aguilar-Bryan L, Bryan J Endocr Rev 2008. 29(3):265-291
	The G53D Mutation in Kir6.2 (KCNJ11) is Associated with Neonatal Diabetes and Motor Dysfunction in Adulthood that is Improved with Sulfonylurea Therapy Koster JC, Cadario F, Peruzzi C, Colombo C, Nichols CG, Barbetti F J Clin Endocrinol Metab 2008. 93(3):1054-1061
	Islet-specific antibody seroconversion in patients with long duration of permanent neonatal diabetes caused by mutations in the KCNJ11 gene Gach A, Wyka K, Malecki MT, Noczynska A, Skupien J, Nazim J, Szalecki M, Bodalski J, Sieradzki J, Mlynarski W Diabetes Care 2007. 30(8):2080-2082
	Transfer to Sulphonylurea Therapy in Adult Subjects With Permanent Neonatal Diabetes Due to KCNJ11-Activating Mutations Malecki MT, Skupien J, Klupa T, Wanic K, Mlynarski W, Gach A, Solecka I, Sieradzki J Diabetes Care 2007. 30(1):147-149